Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Group 5 Pulmonary Hypertension: Multiple Systemic Diseases, Multiple Mechanisms of Pulmonary Hypertension, and Multiple Management Challenges

Author(s): Christopher Barnett*, Samuel B. Brusca, Nicholas Kolaitis and Teresa De Marco

Volume 20, Issue 3, 2024

Published on: 27 February, 2024

Page: [202 - 218] Pages: 17

DOI: 10.2174/011573398X283197240222113135

Price: $65

Abstract

Group 5 pulmonary hypertension (PH) with unclear and/or multifactorial mechanisms includes a wide variety of conditions associated with PH, and the mechanisms by which PH develops vary dramatically depending on the underlying condition. Indeed, in many group 5 conditions, such as sarcoidosis, multiple distinct drivers of PH are present concurrently in a single patient, with the predominant factor depending on the predisposing disease phenotype. For this reason, thorough diagnostic evaluation to most accurately phenotype every patient with group 5 PH is essential. Treatment of these patients should begin by fully characterizing and optimizing the management of their underlying disease, often in conjunction with disease experts. Initial targets of PH treatment include identifying and correcting factors that worsen PH, such as volume overload and hypoxemia, as well as a complete PH evaluation, searching for other undiagnosed causes of PH (e.g., congenital heart disease or chronic thromboembolic disease). Data to guide treatment with therapies specific to pulmonary arterial hypertension (PAH) are inadequate for any specific recommendations, and adverse effects in group 5 patients are common. If these therapies are considered, evaluation by a multidisciplinary team that includes a PH specialist is recommended. Factors in the selection of PAH therapies should include consideration of the dominant physiologic features of the underlying disease, the severity of hemodynamic and right ventricular abnormalities, the risk of adverse drug effects, and any known contraindications to PAH-specific medications based on the underlying condition. Vigilant monitoring following initiation of PAH-specific therapy is critical, as the clinical effects are hard to predict, and untoward events, such as uncovering pulmonary veno-occlusive disease, may occur. Collaborative care by a multidisciplinary team of experts is key to the management of this challenging patient population.

« Previous Next »
Graphical Abstract

[1]
Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53(1): 1801913.
[http://dx.doi.org/10.1183/13993003.01913-2018] [PMID: 30545968]
[2]
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43(38): 3618-731.
[http://dx.doi.org/10.1093/eurheartj/ehac237] [PMID: 36017548]
[3]
Barnett CF, Hsue PY, Machado RF. Pulmonary hypertension. JAMA 2008; 299(3): 324-31.
[http://dx.doi.org/10.1001/jama.299.3.324] [PMID: 18212317]
[4]
Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest 2017; 127(3): 750-60.
[http://dx.doi.org/10.1172/JCI89741] [PMID: 28248201]
[5]
Machado RF, Farber HW. Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders. Clin Chest Med 2013; 34(4): 739-52.
[http://dx.doi.org/10.1016/j.ccm.2013.08.006] [PMID: 24267302]
[6]
Haw A, Palevsky HI. Pulmonary hypertension in chronic hemolytic anemias: Pathophysiology and treatment. Respir Med 2018; 137: 191-200.
[http://dx.doi.org/10.1016/j.rmed.2018.02.020] [PMID: 29605204]
[7]
Wood JC. Pulmonary hypertension in thalassemia: A call to action. Blood 2022; 139(13): 1937-8.
[http://dx.doi.org/10.1182/blood.2021015340] [PMID: 35357479]
[8]
Hill A, Sapsford RJ, Scally A, et al. Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function. Br J Haematol 2012; 158(3): 409-14.
[http://dx.doi.org/10.1111/j.1365-2141.2012.09166.x] [PMID: 22639982]
[9]
Crary SE, Ramaciotti C, Buchanan GR. Prevalence of pulmonary hypertension in hereditary spherocytosis. Am J Hematol 2011; 86(12): E73-6.
[http://dx.doi.org/10.1002/ajh.22182] [PMID: 21953840]
[10]
Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54(1) (Suppl. 1): S43-54.
[http://dx.doi.org/10.1016/j.jacc.2009.04.012] [PMID: 19555858]
[11]
Shilo NR, Morris CR. Pathways to pulmonary hypertension in sickle cell disease: the search for prevention and early intervention. Expert Rev Hematol 2017; 10(10): 875-90.
[http://dx.doi.org/10.1080/17474086.2017.1364989] [PMID: 28817980]
[12]
Prohaska CC, Machado RF. The different facets of sickle cell disease-related pulmonary hypertension. Curr Opin Pulm Med 2021; 27(5): 319-28.
[http://dx.doi.org/10.1097/MCP.0000000000000795] [PMID: 34224433]
[13]
Mehari A, Igbineweka N, Allen D, Nichols J, Thein SL, Weir NA. Abnormal ventilation–perfusion scan is associated with pulmonary hypertension in sickle cell adults. J Nucl Med 2019; 60(1): 86-92.
[http://dx.doi.org/10.2967/jnumed.118.211466] [PMID: 29880507]
[14]
Wood KC, Gladwin MT, Straub AC. Sickle cell disease: At the crossroads of pulmonary hypertension and diastolic heart failure. Heart 2020; 106(8): 562-8.
[http://dx.doi.org/10.1136/heartjnl-2019-314810] [PMID: 31822569]
[15]
Jison ML, Gladwin MT. Hemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. Am J Respir Crit Care Med 2003; 168(1): 3-4.
[http://dx.doi.org/10.1164/rccm.2304002] [PMID: 12826592]
[16]
Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8(12): 1383-9.
[http://dx.doi.org/10.1038/nm1202-799] [PMID: 12426562]
[17]
Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005; 294(1): 81-90.
[http://dx.doi.org/10.1001/jama.294.1.81] [PMID: 15998894]
[18]
Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350(9): 886-95.
[http://dx.doi.org/10.1056/NEJMoa035477] [PMID: 14985486]
[19]
Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006; 107(6): 2279-85.
[http://dx.doi.org/10.1182/blood-2005-06-2373] [PMID: 16291595]
[20]
Machado RF, Anthi A, Steinberg MH, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA 2006; 296(3): 310-8.
[http://dx.doi.org/10.1001/jama.296.3.310] [PMID: 16849664]
[21]
Damy T, Bodez D, Habibi A, et al. Haematological determinants of cardiac involvement in adults with sickle cell disease. Eur Heart J 2016; 37(14): 1158-67.
[http://dx.doi.org/10.1093/eurheartj/ehv555] [PMID: 26516176]
[22]
Gladwin MT, Barst RJ, Gibbs JSR, et al. Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. PLoS One 2014; 9(7): e99489.
[http://dx.doi.org/10.1371/journal.pone.0099489] [PMID: 24988120]
[23]
Fonseca GHH, Souza R, Salemi VMC, Jardim CVP, Gualandro SFM. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J 2012; 39(1): 112-8.
[http://dx.doi.org/10.1183/09031936.00134410] [PMID: 21778170]
[24]
Mehari A, Alam S, Tian X, et al. Hemodynamic predictors of mortality in adults with sickle cell disease. Am J Respir Crit Care Med 2013; 187(8): 840-7.
[http://dx.doi.org/10.1164/rccm.201207-1222OC] [PMID: 23348978]
[25]
Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011; 365(1): 44-53.
[http://dx.doi.org/10.1056/NEJMoa1005565] [PMID: 21732836]
[26]
Brusca SB, Zou Y, Elinoff JM. How low should we go? Potential benefits and ramifications of the pulmonary hypertension hemodynamic definitions proposed by the 6th World Symposium. Curr Opin Pulm Med 2020; 26(5): 384-90.
[http://dx.doi.org/10.1097/MCP.0000000000000699] [PMID: 32701671]
[27]
d’Humières T, Savale L, Inamo J, et al. Cardiovascular phenotypes predict clinical outcomes in sickle cell disease: An echocardiography-based cluster analysis. Am J Hematol 2021; 96(9): 1166-75.
[http://dx.doi.org/10.1002/ajh.26271] [PMID: 34143511]
[28]
Niss O, Taylor MD. Applications of cardiac magnetic resonance imaging in sickle cell disease. Blood Cells Mol Dis 2017; 67: 126-34.
[http://dx.doi.org/10.1016/j.bcmd.2017.08.005] [PMID: 28818577]
[29]
Badawy SM, Liem RI, Rigsby CK, Labotka RJ, DeFreitas RA, Thompson AA. Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease. Br J Haematol 2016; 175(4): 705-13.
[http://dx.doi.org/10.1111/bjh.14277] [PMID: 27507431]
[30]
Porter J, Garbowski M. Consequences and management of iron overload in sickle cell disease. Hematology Am Soc Hematol Educ Program 2013; 2013(1): 447-56.
[http://dx.doi.org/10.1182/asheducation-2013.1.447] [PMID: 24319218]
[31]
Tavares AHJ, Benites BD, Fertrin KY. Myocardial iron overload in sickle cell disease: A rare but potentially fatal complication of transfusion. Transfus Med Rev 2019; 33(3): 170-5.
[http://dx.doi.org/10.1016/j.tmrv.2019.04.001] [PMID: 31153715]
[32]
Graham JK, Mosunjac M, Hanzlick RL, Mosunjac M. Sickle cell lung disease and sudden death: A retrospective/prospective study of 21 autopsy cases and literature review. Am J Forensic Med Pathol 2007; 28(2): 168-72.
[http://dx.doi.org/10.1097/01.paf.0000257397.92466.50] [PMID: 17525572]
[33]
Anthi A, Machado RF, Jison ML, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med 2007; 175(12): 1272-9.
[http://dx.doi.org/10.1164/rccm.200610-1498OC] [PMID: 17379852]
[34]
Yung GL, Channick RN, Fedullo PF, et al. Successful pulmonary thromboendarterectomy in two patients with sickle cell disease. Am J Respir Crit Care Med 1998; 157(5): 1690-3.
[http://dx.doi.org/10.1164/ajrccm.157.5.9710032] [PMID: 9603156]
[35]
Klings ES, Machado RF, Barst RJ, et al. An official american thoracic society clinical practice guideline: Diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med 2014; 189(6): 727-40.
[http://dx.doi.org/10.1164/rccm.201401-0065ST] [PMID: 24628312]
[36]
Machado RF, Barst RJ, Yovetich NA, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 2011; 118(4): 855-64.
[http://dx.doi.org/10.1182/blood-2010-09-306167] [PMID: 21527519]
[37]
Cramer-Bour C, Ruhl AP, Nouraie SM, et al. Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease. Eur J Haematol 2021; 107(1): 54-62.
[http://dx.doi.org/10.1111/ejh.13612] [PMID: 33650125]
[38]
Vachiéry JL, Tedford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left heart disease. Eur Respir J 2019; 53(1): 1801897.
[http://dx.doi.org/10.1183/13993003.01897-2018] [PMID: 30545974]
[39]
Pinto VM, Musallam KM, Derchi G, et al. Mortality in β-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization. Blood 2022; 139(13): 2080-3.
[http://dx.doi.org/10.1182/blood.2021014862] [PMID: 34986266]
[40]
Derchi G, Galanello R, Bina P, et al. Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: A Webthal study. Circulation 2014; 129(3): 338-45.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.002124] [PMID: 24081970]
[41]
Derchi G, Balocco M, Bina P, et al. Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: Results from a long-term follow up. Haematologica 2014; 99(2): e17-8.
[http://dx.doi.org/10.3324/haematol.2013.095810] [PMID: 24497563]
[42]
Karami H, Darvishi-Khezri H, Kosaryan M, Akbarzadeh R, Dabirian M. The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension. Int Med Case Rep J 2018; 12: 1-7.
[http://dx.doi.org/10.2147/IMCRJ.S180602] [PMID: 30588128]
[43]
Tam DH, Farber HW. Pulmonary hypertension and β-thalassemia major: Report of a case, its treatment, and a review of the literature. Am J Hematol 2006; 81(6): 443-7.
[http://dx.doi.org/10.1002/ajh.20603] [PMID: 16680745]
[44]
Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331(9): 574-8.
[http://dx.doi.org/10.1056/NEJM199409013310903] [PMID: 8047081]
[45]
Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120(20): 1961-8.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.874487] [PMID: 19801505]
[46]
Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008; 10(1): 42.
[http://dx.doi.org/10.1186/1532-429X-10-42] [PMID: 18817553]
[47]
Ballas SK, Zeidan AM, Duong VH, DeVeaux M, Heeney MM. The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review. Am J Hematol 2018; 93(7): 943-52.
[http://dx.doi.org/10.1002/ajh.25103] [PMID: 29635754]
[48]
Fraidenburg DR, Machado RF. Pulmonary hypertension associated with thalassemia syndromes. Ann N Y Acad Sci 2016; 1368(1): 127-39.
[http://dx.doi.org/10.1111/nyas.13037] [PMID: 27008311]
[49]
Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333(19): 1253-8.
[http://dx.doi.org/10.1056/NEJM199511093331904] [PMID: 7566002]
[50]
Hill A, Rother RP, Wang X, et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2010; 149(3): 414-25.
[http://dx.doi.org/10.1111/j.1365-2141.2010.08096.x] [PMID: 20230403]
[51]
Kimmig LM, Palevsky HI. Review of the association between splenectomy and chronic thromboembolic pulmonary hypertension. Ann Am Thorac Soc 2016; 13(6): 945-54.
[http://dx.doi.org/10.1513/AnnalsATS.201512-826FR] [PMID: 27058013]
[52]
Palkar AV, Agrawal A, Verma S, Iftikhar A, Miller EJ, Talwar A. Post splenectomy related pulmonary hypertension. World J Respirol 2015; 5(2): 69-77.
[http://dx.doi.org/10.5320/wjr.v5.i2.69] [PMID: 26949600]
[53]
Arkema EV, Cozier YC. Sarcoidosis epidemiology: Recent estimates of incidence, prevalence and risk factors. Curr Opin Pulm Med 2020; 26(5): 527-34.
[http://dx.doi.org/10.1097/MCP.0000000000000715] [PMID: 32701677]
[54]
Baughman RP, Field S, Costabel U, et al. Sarcoidosis in America. Analysis based on health care use. Ann Am Thorac Soc 2016; 13(8): 1244-52.
[http://dx.doi.org/10.1513/AnnalsATS.201511-760OC] [PMID: 27509154]
[55]
Harper LJ, Gerke AK, Wang XF, et al. Income and other contributors to poor outcomes in U.S. Patients with sarcoidosis. Am J Respir Crit Care Med 2020; 201(8): 955-64.
[http://dx.doi.org/10.1164/rccm.201906-1250OC] [PMID: 31825646]
[56]
Rabin DL, Thompson B, Brown KM, et al. Sarcoidosis: Social predictors of severity at presentation. Eur Respir J 2004; 24(4): 601-8.
[http://dx.doi.org/10.1183/09031936.04.00070503] [PMID: 15459139]
[57]
Belperio JA, Shaikh F, Abtin FG, et al. Diagnosis and treatment of pulmonary sarcoidosis. JAMA 2022; 327(9): 856-67.
[http://dx.doi.org/10.1001/jama.2022.1570] [PMID: 35230389]
[58]
Birnie DH, Nery PB, Ha AC, Beanlands RSB. Cardiac sarcoidosis. J Am Coll Cardiol 2016; 68(4): 411-21.
[http://dx.doi.org/10.1016/j.jacc.2016.03.605] [PMID: 27443438]
[59]
Huitema MP, Bakker ALM, Mager JJ, et al. Prevalence of pulmonary hypertension in pulmonary sarcoidosis: The first large European prospective study. Eur Respir J 2019; 54(4): 1900897.
[http://dx.doi.org/10.1183/13993003.00897-2019] [PMID: 31320453]
[60]
Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129(5): 1246-52.
[http://dx.doi.org/10.1378/chest.129.5.1246] [PMID: 16685015]
[61]
Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008; 32(2): 296-302.
[http://dx.doi.org/10.1183/09031936.00175907] [PMID: 18385166]
[62]
Zhang S, Tong X, Zhang T, et al. Prevalence of sarcoidosis-associated pulmonary hypertension: A systematic review and meta-analysis. Front Cardiovasc Med 2022; 8: 809594.
[http://dx.doi.org/10.3389/fcvm.2021.809594] [PMID: 35111830]
[63]
Savale L, Huitema M, Shlobin O, et al. WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. Eur Respir Rev 2022; 31(163): 210165.
[http://dx.doi.org/10.1183/16000617.0165-2021] [PMID: 35140103]
[64]
Parikh KS, Dahhan T, Nicholl L, et al. Clinical features and outcomes of patients with sarcoidosis-associated pulmonary hypertension. Sci Rep 2019; 9(1): 4061.
[http://dx.doi.org/10.1038/s41598-019-40030-w] [PMID: 30858405]
[65]
Bonham CA, Oldham JM, Gomberg-Maitland M, Vij R. Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: A retrospective case series. Chest 2015; 148(4): 1055-62.
[http://dx.doi.org/10.1378/chest.14-2546] [PMID: 26437815]
[66]
Kirkil G, Lower EE, Baughman RP. Predictors of mortality in pulmonary sarcoidosis. Chest 2018; 153(1): 105-13.
[http://dx.doi.org/10.1016/j.chest.2017.07.008] [PMID: 28728933]
[67]
Gupta R, Zheng M, Gangemi AJ, et al. Predictors of lung transplant waitlist mortality for sarcoidosis. Respir Med 2022; 205: 107008.
[http://dx.doi.org/10.1016/j.rmed.2022.107008] [PMID: 36371932]
[68]
Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: Mechanisms, haemodynamics and prognosis. Thorax 2005; 61(1): 68-74.
[http://dx.doi.org/10.1136/thx.2005.042838] [PMID: 16227329]
[69]
Swigris JJ, Olson AL, Huie TJ, et al. Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest 2011; 140(5): 1261-6.
[http://dx.doi.org/10.1378/chest.11-0324] [PMID: 21565969]
[70]
Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J 2017; 50(4): 1700465.
[http://dx.doi.org/10.1183/13993003.00465-2017] [PMID: 29051269]
[71]
Barnett CF, Bonura EJ, Nathan SD, et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 2009; 135(6): 1455-61.
[http://dx.doi.org/10.1378/chest.08-1881] [PMID: 19118270]
[72]
Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: Outcome with long-term epoprostenol treatment. Chest 2006; 130(5): 1481-8.
[http://dx.doi.org/10.1378/chest.130.5.1481] [PMID: 17099027]
[73]
Milman N, Burton CM, Iversen M, Videbæk R, Jensen CV, Carlsen J. Pulmonary hypertension in end-stage pulmonary sarcoidosis: Therapeutic effect of sildenafil? J Heart Lung Transplant 2008; 27(3): 329-34.
[http://dx.doi.org/10.1016/j.healun.2007.11.576] [PMID: 18342757]
[74]
Nathan SD, Fernandes P, Psotka M, et al. Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the pulmonary vascular research institute’s innovative drug development initiative—group 3 pulmonary hypertension. Pulm Circ 2022; 12(4): e12178.
[http://dx.doi.org/10.1002/pul2.12178] [PMID: 36578976]
[75]
Ford HJ, Baughman RP, Aris R, Engel P, Donohue JF. Tadalafil therapy for sarcoidosis-associated pulmonary hypertension. Pulm Circ 2016; 6(4): 557-62.
[http://dx.doi.org/10.1086/688775] [PMID: 28090299]
[76]
Judson MA, Highland KB, Kwon S, et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28(2): 139-45.
[PMID: 22117505]
[77]
Baughman RP, Judson MA, Lower EE, et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26(2): 110-20.
[PMID: 20560291]
[78]
Abston E, Moll M, Hon S, Govender P, Berman J, Farber H. Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37(2): 184-91.
[PMID: 33093782]
[79]
Baughman RP, Culver DA, Cordova FC, et al. Bosentan for sarcoidosis-associated pulmonary hypertension: A double-blind placebo controlled randomized trial. Chest 2014; 145(4): 810-7.
[http://dx.doi.org/10.1378/chest.13-1766] [PMID: 24177203]
[80]
Baughman RP, Shlobin OA, Gupta R, et al. Riociguat for sarcoidosis-associated pulmonary hypertension. Chest 2022; 161(2): 448-57.
[http://dx.doi.org/10.1016/j.chest.2021.07.2162] [PMID: 34363816]
[81]
Le Pavec J, Lorillon G, Jaïs X, et al. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: Clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 2012; 142(5): 1150-7.
[http://dx.doi.org/10.1378/chest.11-2490] [PMID: 22459770]
[82]
Goyal G, Tazi A, Go RS, et al. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood 2022; 139(17): 2601-21.
[http://dx.doi.org/10.1182/blood.2021014343] [PMID: 35271698]
[83]
Jutant EM, Girerd B, Jaïs X, et al. Pulmonary hypertension associated with neurofibromatosis type 1. Eur Respir Rev 2018; 27(149): 180053.
[http://dx.doi.org/10.1183/16000617.0053-2018] [PMID: 30158278]
[84]
Alves Júnior SF, Zanetti G, Alves de Melo AS, et al. Neurofibromatosis type 1: State-of-the-art review with emphasis on pulmonary involvement. Respir Med 2019; 149: 9-15.
[http://dx.doi.org/10.1016/j.rmed.2019.01.002] [PMID: 30885426]
[85]
Kishnani PS, Austin SL, Abdenur JE, et al. Diagnosis and management of glycogen storage disease type I: A practice guideline of the american college of medical genetics and genomics. Genet Med 2014; 16(11): e1-e29.
[http://dx.doi.org/10.1038/gim.2014.128] [PMID: 25356975]
[86]
Ueno M, Murakami T, Takeda A, Kubota M. Efficacy of oral sildenafil in a beraprost-treated patient with severe pulmonary hypertension secondary to type I glycogen storage disease. Circ J 2009; 73(10): 1965-8.
[http://dx.doi.org/10.1253/circj.CJ-08-0181]
[87]
Lee TM, Berman-Rosenzweig ES, Slonim AE, Chung WK. Two cases of pulmonary hypertension associated with type III glycogen storage disease. JIMD Rep 2011; 1: 79-82.
[http://dx.doi.org/10.1007/8904_2011_20] [PMID: 23430832]
[88]
Oliveros E, Vaidya A. Metabolic disorders of pulmonary hypertension. Adv Pulm Hypertens 2021; 20(2): 35-9.
[89]
Lo SM, Liu J, Chen F, et al. Pulmonary vascular disease in Gaucher disease: Clinical spectrum, determinants of phenotype and long-term outcomes of therapy. J Inherit Metab Dis 2011; 34(3): 643-50.
[http://dx.doi.org/10.1007/s10545-011-9313-9] [PMID: 21445609]
[90]
Mistry PK, Sirrs S, Chan A, et al. Pulmonary hypertension in type 1 Gaucher’s disease: Genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 2002; 77(1-2): 91-8.
[http://dx.doi.org/10.1016/S1096-7192(02)00122-1] [PMID: 12359135]
[91]
Navaneethan SD, Roy J, Tao K, et al. Prevalence, predictors, and outcomes of pulmonary hypertension in CKD. J Am Soc Nephrol 2016; 27(3): 877-86.
[http://dx.doi.org/10.1681/ASN.2014111111] [PMID: 26386072]
[92]
Walther CP, Nambi V, Hanania NA, Navaneethan SD. Diagnosis and management of pulmonary hypertension in patients with CKD. Am J Kidney Dis 2020; 75(6): 935-45.
[http://dx.doi.org/10.1053/j.ajkd.2019.12.005] [PMID: 32199709]
[93]
O’Leary JM, Assad TR, Xu M, et al. Pulmonary hypertension in patients with chronic kidney disease: Invasive hemodynamic etiology and outcomes. Pulm Circ 2017; 7(3): 674-83.
[http://dx.doi.org/10.1177/2045893217716108] [PMID: 28660793]
[94]
Edmonston DL, Parikh KS, Rajagopal S, et al. Pulmonary hypertension subtypes and mortality in CKD. Am J Kidney Dis 2020; 75(5): 713-24.
[http://dx.doi.org/10.1053/j.ajkd.2019.08.027] [PMID: 31732231]
[95]
Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease. Circulation 2021; 143(11): 1157-72.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.050686] [PMID: 33720773]
[96]
Warner ED, Brailovsky Y, Oliveros E, Bhardwaj A, Rajapreyar IN. High-output heart failure, pulmonary hypertension and right ventricular failure in patients with arteriovenous fistulas: A call to action. J Card Fail 2023; 29(6): 979-81.
[http://dx.doi.org/10.1016/j.cardfail.2023.03.015] [PMID: 37004865]
[97]
Bernelot Moens SJ, Verweij SL, van der Valk FM, et al. Arterial and cellular inflammation in patients with CKD. J Am Soc Nephrol 2017; 28(4): 1278-85.
[http://dx.doi.org/10.1681/ASN.2016030317] [PMID: 27799487]
[98]
Hussain SMA. Tumor embolism and acute arterial occlusion: A systematic review. Surgery Open Science 2022; 10: 216-22.
[http://dx.doi.org/10.1016/j.sopen.2022.10.006] [PMID: 36389271]
[99]
Langer F, Amirkhosravi A, Ingersoll SB, et al. Experimental metastasis and primary tumor growth in mice with hemophilia A. J Thromb Haemost 2006; 4(5): 1056-62.
[http://dx.doi.org/10.1111/j.1538-7836.2006.01883.x] [PMID: 16689759]
[100]
Godbole R, Ghatol A, Betancourt J, Sacoolidge J, Kamangar N. Pulmonary tumor thrombotic microangiopathy: Clinical, radiologic, and histologic correlation. J Clin Imaging Sci 2015; 5: 44.
[http://dx.doi.org/10.4103/2156-7514.161978] [PMID: 26312142]
[101]
Uruga H, Fujii T, Kurosaki A, et al. Pulmonary tumor thrombotic microangiopathy: A clinical analysis of 30 autopsy cases. Intern Med 2013; 52(12): 1317-23.
[http://dx.doi.org/10.2169/internalmedicine.52.9472] [PMID: 23774540]
[102]
Okubo Y, Wakayama M, Kitahara K, et al. Pulmonary tumor thrombotic microangiopathy induced by gastric carcinoma: Morphometric and immunohistochemical analysis of six autopsy cases. Diagn Pathol 2011; 6(1): 27.
[http://dx.doi.org/10.1186/1746-1596-6-27] [PMID: 21450103]
[103]
Bak M, Kim M, Lee B, et al. Clinical course of suspected diagnosis of pulmonary tumor thrombotic microangiopathy: A 10-year experience of rapid progressive right ventricular failure syndrome in advanced cancer patients. Korean Circ J 2023; 53(3): 170-84.
[http://dx.doi.org/10.4070/kcj.2022.0252] [PMID: 36914606]
[104]
Chinen K, Tokuda Y, Fujiwara M, Fujioka Y. Pulmonary tumor thrombotic microangiopathy in patients with gastric carcinoma: An analysis of 6 autopsy cases and review of the literature. Pathol Res Pract 2010; 206(10): 682-9.
[http://dx.doi.org/10.1016/j.prp.2010.05.002] [PMID: 20554399]
[105]
Fujita J, Hummel K, Xu Y. Pulmonary tumor thrombotic microangiopathy caused by metastatic ovarian high-grade serous carcinoma: A case report and literature review. Cardiovasc Pathol 2023; 65: 107526.
[http://dx.doi.org/10.1016/j.carpath.2023.107526] [PMID: 36781067]
[106]
Pinto Pereira J, Lelotte J, Ghaye B, Laterre PF, Hantson P. Pulmonary tumor thrombotic microangiopathy in a patient with a metastatic urothelial carcinoma. Urol Case Rep 2021; 38: 101668.
[http://dx.doi.org/10.1016/j.eucr.2021.101668] [PMID: 33889498]
[107]
Hotta M, Ishida M, Kojima F, Iwai Y, Okabe H. Pulmonary tumor thrombotic microangiopathy caused by lung adenocarcinoma: Case report with review of the literature. Oncol Lett 2011; 2(3): 435-7.
[http://dx.doi.org/10.3892/ol.2011.270] [PMID: 22866100]
[108]
Godbole RH, Saggar R, Kamangar N. Pulmonary tumor thrombotic microangiopathy: A systematic review. Pulm Circ 2019; 9(2): 1-13.
[http://dx.doi.org/10.1177/2045894019851000] [PMID: 31032740]
[109]
Godbole R, Saggar R, Zider A, et al. Insights on pulmonary tumor thrombotic microangiopathy: A seven-patient case series. Pulm Circ 2017; 7(4): 813-20.
[http://dx.doi.org/10.1177/2045893217728072] [PMID: 28782988]
[110]
Onoda H, Imamura T, Inao K, Kinugawa K. How to diagnose and treat pulmonary tumor thrombotic microangiopathy. Int Heart J 2020; 61(2): 409-12.
[http://dx.doi.org/10.1536/ihj.19-549] [PMID: 32173712]
[111]
Febres-Aldana CA, Wymer DT, Burke WF III, Vincentelli C. Recurrent metastatic breast cancer manifesting as pulmonary tumor thrombotic microangiopathy with interstitial pulmonary fibrosis and infarcts: A clinicopathological correlation. Respir Med Case Rep 2019; 28: 100958.
[http://dx.doi.org/10.1016/j.rmcr.2019.100958] [PMID: 31720206]
[112]
Patrignani A, Purcaro A, Calcagnoli F, Mandolesi A, Bearzi I, Ciampani N. Pulmonary tumor thrombotic microangiopathy. J Cardiovasc Med 2014; 15(11): 828-33.
[http://dx.doi.org/10.2459/JCM.0b013e328354e473] [PMID: 22710763]
[113]
Minatsuki S, Miura I, Yao A, et al. Platelet-derived growth factor receptor-tyrosine kinase inhibitor, imatinib, is effective for treating pulmonary hypertension induced by pulmonary tumor thrombotic microangiopathy. Int Heart J 2015; 56(2): 245-8.
[http://dx.doi.org/10.1536/ihj.14-220] [PMID: 25740390]
[114]
Higo K, Kubota K, Takeda A, Higashi M, Ohishi M. Successful antemortem diagnosis and treatment of pulmonary tumor thrombotic microangiopathy. Intern Med 2014; 53(22): 2595-9.
[http://dx.doi.org/10.2169/internalmedicine.53.2379] [PMID: 25400181]
[115]
Kayatani H, Matsuo K, Ueda Y, et al. Pulmonary tumor thrombotic microangiopathy diagnosed antemortem and treated with combination chemotherapy. Intern Med 2012; 51(19): 2767-70.
[http://dx.doi.org/10.2169/internalmedicine.51.7682] [PMID: 23037471]
[116]
Purga SL, Narula N, Horn EM, Karas MG. Pulmonary tumour thrombotic microangiopathy as a cause of new-onset pulmonary hypertension in a patient with metastatic low-grade serous ovarian cancer. BMJ Case Rep 2015; 2015: bcr 2015211890.
[http://dx.doi.org/10.1136/bcr-2015-211890]
[117]
Fukada I, Araki K, Minatsuki S, et al. Imatinib alleviated pulmonary hypertension caused by pulmonary tumor thrombotic microangiopathy in a patient with metastatic breast cancer. Clin Breast Cancer 2015; 15(2): e167-70.
[http://dx.doi.org/10.1016/j.clbc.2014.10.008] [PMID: 25468406]
[118]
Endicott-Yazdani T, Ghazi A, Armstrong D, Guileyardo J, Schuller D. Fatal pulmonary tumor thrombotic microangiopathy caused by undiagnosed metastatic gastric adenocarcinoma. Proc Bayl Univ Med Cent 2015; 28(4): 482-3.
[http://dx.doi.org/10.1080/08998280.2015.11929315] [PMID: 26424948]
[119]
Carter BW, de Groot PM, Godoy MCB, Marom EM, Wu CC. Imaging of the mediastinum: Vascular lesions as a potential pitfall. Semin Roentgenol 2015; 50(3): 241-50.
[http://dx.doi.org/10.1053/j.ro.2015.01.015] [PMID: 26002246]
[120]
Lin J, Jimenez CA. Acute mediastinitis, mediastinal granuloma, and chronic fibrosing mediastinitis: A review. Semin Diagn Pathol 2022; 39(2): 113-9.
[http://dx.doi.org/10.1053/j.semdp.2021.06.008] [PMID: 34176697]
[121]
Rossi SE, McAdams HP, Rosado-de-Christenson ML, Franks TJ, Galvin JR. Fibrosing mediastinitis. Radiographics 2001; 21(3): 737-57.
[http://dx.doi.org/10.1148/radiographics.21.3.g01ma17737] [PMID: 11353121]
[122]
Abu-Omar Y, Kocher GJ, Bosco P, et al. European association for cardio-thoracic surgery expert consensus statement on the prevention and management of mediastinitis. Eur J Cardiothorac Surg 2017; 51(1): 10-29.
[http://dx.doi.org/10.1093/ejcts/ezw326] [PMID: 28077503]
[123]
Deshwal H, Ghosh S, Magruder K, Bartholomew JR, Montgomery J, Mehta AC. A review of endovascular stenting for superior vena cava syndrome in fibrosing mediastinitis. Vasc Med 2020; 25(2): 174-83.
[http://dx.doi.org/10.1177/1358863X19884130] [PMID: 31804157]
[124]
Wang A, Su H, Duan Y, et al. Pulmonary hypertension caused by fibrosing mediastinitis. JACC: Asia 2022; 2(3): 218-34.
[http://dx.doi.org/10.1016/j.jacasi.2021.11.016] [PMID: 36338410]
[125]
Peikert T, Colby TV, Midthun DE, et al. Fibrosing mediastinitis. Medicine 2011; 90(6): 412-23.
[http://dx.doi.org/10.1097/MD.0b013e318237c8e6] [PMID: 22033450]
[126]
Jain N, Chauhan U, Puri SK, Agrawal S, Garg L. Fibrosing mediastinitis: When to suspect and how to evaluate? BJR Case Rep 2016; 2(1): 20150274.
[http://dx.doi.org/10.1259/bjrcr.20150274] [PMID: 30364448]
[127]
Seferian A, Steriade A, Jaïs X, et al. Pulmonary hypertension complicating fibrosing mediastinitis. Medicine 2015; 94(44): e1800.
[http://dx.doi.org/10.1097/MD.0000000000001800] [PMID: 26554778]
[128]
Pfitzenmeyer P, Foucher P, Dennewald G, et al. Pleuropulmonary changes induced by ergoline drugs. Eur Respir J 1996; 9(5): 1013-9.
[http://dx.doi.org/10.1183/09031936.96.09051013] [PMID: 8793465]
[129]
Manyeruke F, Perumal R, Symons G, Mottay L. Idiopathic fibrosing mediastinitis. Afr J Thorac Crit Care Med 2021; 27(2): 61.
[http://dx.doi.org/10.7196/AJTCCM.2021.v27i2.064] [PMID: 34430869]
[130]
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023; 63(2)
[http://dx.doi.org/10.1183/13993003.00879-2022]
[131]
Li Y, Meng X, Wang Y, Yang Y, Lu X. Fibrosing mediastinitis with pulmonary hypertension as a complication of pulmonary vein stenosis. Medicine 2018; 97(4): e9694.
[http://dx.doi.org/10.1097/MD.0000000000009694] [PMID: 29369193]
[132]
Weinstein JB, Aronberg DJ, Sagel SS. CT of fibrosing mediastinitis: Findings and their utility. AJR Am J Roentgenol 1983; 141(2): 247-51.
[http://dx.doi.org/10.2214/ajr.141.2.247] [PMID: 6603112]
[133]
Sherrick AD, Brown LR, Harms GF, Myers JL. The radiographic findings of fibrosing mediastinitis. Chest 1994; 106(2): 484-9.
[http://dx.doi.org/10.1378/chest.106.2.484] [PMID: 7774324]
[134]
Zhou M, Li B, Chen Y, et al. Chest X-ray features facilitate screening for pulmonary hypertension caused by fibrosing mediastinitis. Ther Adv Chronic Dis 2022; 13: 20406223221143245.
[http://dx.doi.org/10.1177/20406223221143245] [PMID: 36583160]
[135]
Garrana SH, Buckley JR, Rosado-de-Christenson ML, Martínez-Jiménez S, Muñoz P, Borsa JJ. Multimodality imaging of focal and diffuse fibrosing mediastinitis. Radiographics 2019; 39(3): 651-67.
[http://dx.doi.org/10.1148/rg.2019180143] [PMID: 30951437]
[136]
Devaraj A, Griffin N, Nicholson AG, Padley SPG. Computed tomography findings in fibrosing mediastinitis. Clin Radiol 2007; 62(8): 781-6.
[http://dx.doi.org/10.1016/j.crad.2007.03.002] [PMID: 17604768]
[137]
Westerly BD, Johnson GB, Maldonado F, Utz JP, Specks U, Peikert T. Targeting B lymphocytes in progressive fibrosing mediastinitis. Am J Respir Crit Care Med 2014; 190(9): 1069-71.
[http://dx.doi.org/10.1164/rccm.201407-1258LE] [PMID: 25360730]
[138]
Mathisen DJ, Grillo HC. Clinical manifestation of mediastinal fibrosis and histoplasmosis. Ann Thorac Surg 1992; 54(6): 1053-8.
[http://dx.doi.org/10.1016/0003-4975(92)90069-G] [PMID: 1449286]
[139]
Loyd J, Tillman BF, Atkinson JB, Des Prez RM. Mediastinal fibrosis complicating histoplasmosis. Medicine 1988; 67(5): 295-310.
[http://dx.doi.org/10.1097/00005792-198809000-00002] [PMID: 3045478]
[140]
Fender EA, Widmer RJ, Knavel Koepsel EM, et al. Catheter based treatments for fibrosing mediastinitis. Catheter Cardiovasc Interv 2019; 94(6): 878-85.
[http://dx.doi.org/10.1002/ccd.28152] [PMID: 30790443]
[141]
Albers EL, Pugh ME, Hill KD, Wang L, Loyd JE, Doyle TP. Percutaneous vascular stent implantation as treatment for central vascular obstruction due to fibrosing mediastinitis. Circulation 2011; 123(13): 1391-9.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.949180] [PMID: 21422386]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy